Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson’s disease

Major depressive disorder (MDD) occurs in a small proportion of patients with Parkinson’s disease (PD) and reduces their quality of life. We performed a randomized sham-controlled study to evaluate the effect of high-frequency (HF) repetitive transcranial magnetic stimulation (rTMS) of the left dors...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2016-07, Vol.263 (7), p.1442-1448
Main Authors: Shin, Hae-Won, Youn, Young C., Chung, Sun J., Sohn, Young H.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antidepressants
Antiparkinson Agents - therapeutic use
Depressive Disorder, Major - etiology
Depressive Disorder, Major - therapy
Female
Follow-Up Studies
Humans
Levodopa - therapeutic use
Male
Medicine
Medicine & Public Health
Mental depression
Mental Status Schedule
Middle Aged
Neurology
Neuroradiology
Neurosciences
Original Communication
Parkinson Disease - complications
Parkinson Disease - drug therapy
Parkinson's disease
Single-Blind Method
Statistics, Nonparametric
Transcranial magnetic stimulation
Transcranial Magnetic Stimulation - methods
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Major depressive disorder (MDD) occurs in a small proportion of patients with Parkinson’s disease (PD) and reduces their quality of life. We performed a randomized sham-controlled study to evaluate the effect of high-frequency (HF) repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (DLPFC) on MDD in patients with PD. Ten patients participated to a real-rTMS group and eight patients to a sham-rTMS group. Evaluations were performed at baseline, 2 and 6 weeks after rTMS treatment. All participants underwent examinations of depression rating scales, including the Hamilton Rating Scale, the Montgomery–Asberg Depression Rating Scale (MADRS), and the Beck Depression Inventory (BDI) and the motor part of the Unified Parkinson Disease Rating Scale (UPDRS-III). The real-rTMS group had improved scores on HRS and the MADRS after 10 sessions, and these beneficial effects persisted for 6 weeks after the initial session. The BDI score did not change immediately after the sessions. The sham-rTMS group had no significant changes in any of the depression rating scales. The UPDRS-III did not change in either group. HF-rTMS of the left DLPFC is an effective treatment for MDD in patients with PD.
ISSN:0340-5354
1432-1459
DOI:10.1007/s00415-016-8160-x